Literature DB >> 19222412

Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy.

J R Gray1, E Leung, J Scales.   

Abstract

BACKGROUND: Data available regarding patient perspectives on ulcerative colitis (UC) and their preferences and satisfaction with therapy are limited. AIMS: To examine the preferences of UC patients to understand better what they look for in a therapy when managing their disease, as this may influence overall medication adherence.
METHODS: The study surveyed 100 Canadian UC patients on topics including educational resources used to learn about the disease, medication attributes that are most valued and preferred by the patient and satisfaction with current therapy.
RESULTS: Overall, efficacy- and safety-related medication attributes were rated by patients to be more important than those related to dosing regimen (e.g. dosing frequency, number of pills), cost and formulary coverage. In pair-wise comparisons of specific medication attributes, UC patients rated speed of symptom relief and few side effects as the most important factors when considering a UC medication (preferred on average 84% and 74% of the time respectively).
CONCLUSION: This study provides insight into UC patient preferences and satisfaction with therapy that may be important when counselling on treatment options, and generates relevant discussions on adherence. Larger studies may be warranted to examine further how these findings can be extrapolated to broader UC populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222412     DOI: 10.1111/j.1365-2036.2009.03972.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

1.  Satisfaction with patient-doctor relationships in inflammatory bowel diseases: examining patient-initiated change of specialist.

Authors:  Daniel R van Langenberg; Jane M Andrews
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

Review 2.  Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data.

Authors:  Meenakshi Bewtra; F Reed Johnson
Journal:  Patient       Date:  2013       Impact factor: 3.883

Review 3.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

4.  Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.

Authors:  Siddharth Singh; James A Proudfoot; Parambir S Dulai; Ronghui Xu; Brian G Feagan; William J Sandborn; Vipul Jairath
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-18       Impact factor: 11.382

5.  The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model.

Authors:  Jennifer Devlen; Kathleen Beusterien; Linnette Yen; Awais Ahmed; Adam S Cheifetz; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2014-03       Impact factor: 5.325

6.  Perceived Emotional and Psychological Impact of Ulcerative Colitis on Outpatients in Spain: UC-LIFE Survey.

Authors:  Antonio López-Sanromán; Daniel Carpio; Xavier Calvet; Cristina Romero; Luis Cea-Calvo; Berta Juliá; Federico Argüelles-Arias
Journal:  Dig Dis Sci       Date:  2016-11-05       Impact factor: 3.199

7.  Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.

Authors:  Nghia H Nguyen; Mathurin Fumery; Parambir S Dulai; Larry J Prokop; William J Sandborn; Mohammad Hassan Murad; Siddharth Singh
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-08-17

8.  Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.

Authors:  Sunanda V Kane; Michael Sumner; Dory Solomon; Matthew Jenkins
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

9.  Long-term treatment acceptance: what is it, and how can it be assessed?

Authors:  Claire Marant; Juliette Longin; Rémi Gauchoux; Benoit Arnould; Céderic Spizak; Alexia Marrel; Donald L Patrick; Eric Van Ganse
Journal:  Patient       Date:  2012       Impact factor: 3.883

10.  Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis.

Authors:  Sydney Greenberg; Hans H Herfarth; Edward L Barnes
Journal:  Inflamm Intest Dis       Date:  2019-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.